Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Penn study shows how next-generation diabetic drugs could work more selectively

28.01.2005


Understanding molecular double action of tzds to reduce side effects



In an attempt to find a new generation of diabetic drugs that will minimize side effects, researchers at the University of Pennsylvania School of Medicine report a new understanding of how thiazolidinediones (TZDs), widely used diabetic medications, work in fat cells. With yearly sales exceeding billions of dollars, TZDs – such as rosiglitazone maleate (Avandia) and pioglitazone hydrochloride (Actos) – help to maintain diabetics’ blood-sugar levels.

In fat cells, TZDs turn on a small set of genes, which aren’t normally turned on, by targeting the receptor PPARã. To tease out how the medications work specifically, the investigators set out to determine the difference between the genes that are ordinarily turned on in fat cells and the genes that are turned on only when diabetics are given the TZDs.


A new study from the laboratory of Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at Penn, has found that PPARã can turn genes both on and off. "What regulates it, in this case, is the drug, which is acting as a switch to turn genes on," says Lazar. "This paper shows that we can separate the two different aspects of the drug’s action on fat cells." These findings appear in the January 28th online edition of Genes & Development and will appear in the February 15th print issue.

Knowing how to turn a gene off may permit researchers to develop drugs that would decrease TZD-related side effects such as weight gain and edema. Indeed, preclinical research is already underway to design drugs called SPPARMs, selective PPARã modulators, which would specifically target genes in fat cells that can turn off the molecular pathways that may lead to these serious side effects.

Working with mouse fat cells, Lazar’s study suggests that one way to get gene-selective actions would be to target this ability to turn off genes without affecting the ability to turn others on. "Since these are separate processes, one through one type of molecular action and one through another, our work shows that this is feasible," says Lazar

How would a SPPARM work? TZDs turn genes on and off by working with molecules called coactivators and corepressors. In addition to its beneficial role, TZDs turn fibroblasts into fat cells by enlisting more coactivators than normal, thus leading to weight gain. The goal is to design a SPPARM that will reduce interaction with corepressors, but increase interaction with coactivators, to separate anti-diabetic effects and weight gain.

"We should be optimistic about finding a new type of drug with the same fat-cell target as TZDs, but which is a selective regulator of gene expression in such a way that will increase the benefit-to-risk ratio of the diabetes treatment," says Lazar.

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>